Last reviewed · How we verify

Intravenous Morphine

Columbia University · FDA-approved active Small molecule Quality 5/100

Intravenous Morphine, marketed by Columbia University, is a well-established analgesic in the healthcare sector. The drug holds a key composition patent expiring in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameIntravenous Morphine
Also known asMorphine, Morphine group, duramorph, Intravenous esmolol, venous blood samples
SponsorColumbia University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: